Saturday 17 October 2026 Export SVA’s income statement to Excel — free account

Sinovac Biotech, Ltd.

Sinovac Biotech, Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $386.0 million, up 6.82% from fiscal 2024.

6.47 0.00 0.00%

Follow SVA

Alert me

Market cap: $642.4M
P/E: 0.2×
Fwd P/E: −3.8×
Dividend yield: —
F-score: 3/9
Altman Z: 1.22
Beneish M: −2.38
Dividend safety: 20/100

Overview Business Profile Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 39.83%

Capital & Financial Ratios $m

Market Cap 642.44

Revenue 10,026.00

Net Income (83.89)

Free Cash Flow (786.38)

Net Debt (5,818.33)

Current Ratio 6.07

Debt/Equity 0.06

P/E ratio 0.19

Fwd P/E (3.81)

P/S ratio 0.06

P/B ratio 0.10

Past 5Y EPS Growth —

This Y EPS Growth —

Next Y EPS Growth —

Next Y revenue growth (99.95%)

Next 5Y EPS Growth —

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/E against its own 10 years 54.08%

10-year low 10-year high

P/S against its own 10 years 47.69%

10-year low 10-year high

P/B against its own 10 years 33.35%

10-year low 10-year high

EV/FCF against its own 10 years 0.56%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2020	Powerpack
2019	Powerpack
2018	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	11,024	10,216	6,640	6,200
Receivables	425	316	313	294
Inventory	136	97	94	107
Other	—	—	—	—
	11,597	10,645	7,064	6,624

	2023	2024	2025	Q'26
Payables	989	803	605	250
ST’ Debt	76	212	229	148
Other	2	2	3	5
	1,293	1,452	1,540	1,091

Compound Annual Growth %

	10y	5y	3y
Sales	19.07%	(5.44%)	(36.29%)
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	46.92%	41.69%	(20.46%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	386
’24	—	—	—	—	361
’23	—	—	—	—	470
’22	—	—	—	—	1,493
’21	—	—	—	—	19,375
’20	15	52	115	327	511

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	(322)	—	—	—
’25	—	(311)	—	—	(512)
’24	—	(439)	—	—	(57)
’23	—	—	—	—	139
’22	—	—	—	—	(771)
’21	—	—	—	—	15,353
’20	(18)	2	14	481	479

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	—	(341)	—	—	—
’25	—	(337)	—	—	(561)
’24	—	(496)	—	—	(154)
’23	—	(93)	—	—	(18)
’22	—	(279)	—	152	(1,174)
’21	—	(431)	—	6,265	14,633
’20	(21)	(31)	(19)	423	352

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	—	—	—	—	—
’25	—	—	—	—	(0.83)
’24	—	—	—	—	1.27
’23	—	—	—	—	(1.06)
’22	—	—	—	—	1.00
’21	—	—	—	—	74.27
’20	(0.07)	(0.05)	0.10	0.96	0.97

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	4.38	4.60	5.73	0.00	6.47	6.47	6.47	6.47	6.47	6.47	Analyst estimates 2026–2028 Powerpack
	High	7.16	8.11	8.75	7.10	6.47	6.47	6.47	6.47	6.47	6.47
People
People	Employees	835	800	870	1,043	2,212	5,505	4,275	3,261	2,643	3,008
	Revenue/emp, $m	0.09	0.22	0.26	0.24	0.23	3.52	0.35	0.14	0.14	0.13
Income, $m
Income, $m	Revenue	72	174	230	246	511	19,375	1,493	470	361	386
	Gross margin, %	69.08	88.39	89.23	86.80	86.84	94.47	54.15	68.77	61.07	67.87
	EBT	0	45	47	71	217	17,563	25	(84)	43	(262)
	EBT margin, %	(0.54)	25.84	20.28	28.78	42.42	90.65	1.69	(17.97)	11.85	(67.90)
	Net income	(3)	37	36	65	185	14,459	88	(121)	41	(199)
	Depreciation	5	5	5	5	4	85	155	158	111	99
Per share, $
Per share, $	Revenue	1.27	3.06	3.55	2.59	5.16	195.09	15.00	6.55	5.03	5.37
	Earnings	(0.01)	0.45	0.34	0.42	1.06	85.20	1.08	(1.06)	1.27	(0.83)
	Cash flow	(0.27)	1.05	0.12	0.41	4.85	154.59	(7.75)	1.93	(0.79)	(7.13)
	Capex	(0.22)	(0.21)	(0.09)	(0.11)	(1.29)	(7.25)	(4.05)	(2.17)	(1.36)	(0.68)
	Free cash flow	(0.49)	0.84	0.04	0.30	3.56	147.34	(11.79)	(0.24)	(2.15)	(7.81)
	Book value	2.28	3.11	4.51	3.71	11.33	139.72	127.76	162.08	143.24	89.01
	Shares, m	57	57	65	95	99	99	100	72	72	72
Valuation, ×
Valuation, ×	P/E	0.00	13.59	12.44	16.18	6.05	0.07	0.08	0.19	0.19	0.19
	P/S	4.64	1.95	1.96	2.49	1.25	0.03	0.03	0.06	0.06	0.06
	P/B	2.59	3.03	1.54	1.74	0.57	0.07	0.07	0.05	0.06	0.10
	EV/Sales	4.30	1.63	1.25	1.69	(0.99)	(0.64)	(0.51)	(1.02)	(0.96)	(0.88)
	EV/FCF	(11.08)	8.03	121.62	14.58	(1.43)	(0.83)	(0.76)	(2.17)	12.01	12.47
Cash, $m
Cash, $m	Operating cash flow	(15)	60	8	39	479	15,353	(771)	139	(57)	(512)
	Capex	(13)	(12)	(6)	(11)	(128)	(720)	(403)	(156)	(97)	(49)
	Free cash flow	(28)	48	2	28	352	14,633	(1,174)	(18)	(154)	(561)
Balance, $m
Balance, $m	Working capital	64	111	226	262	881	12,502	11,035	10,305	9,193	5,524
	Total debt	41	40	14	7	41	20	12	254	376	495
	Net debt	(25)	(76)	(163)	(199)	(1,144)	(13,406)	(11,309)	(10,770)	(9,840)	(6,145)
	Shareholders’ equity	130	177	292	352	1,120	13,876	12,713	11,642	10,293	6,396
Returns, %
Returns, %	ROA	(0.29)	10.11	6.51	9.68	8.87	90.74	0.70	(0.10)	0.70	(0.57)
	ROIC	0.30	28.04	22.00	27.93	0.00	2,332.85	(20.75)	(51.13)	(69.65)	(121.75)
	ROE	(0.45)	16.82	9.29	12.36	14.18	112.85	0.81	(0.11)	0.83	(0.72)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Dec 2020

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
SVA Sinovac Biotech, Ltd.	$642.4M	0.2×	— (loss-making)	−98.73% (below 0%: shrinking)	−99.77% (below 0%: shrinking)	−324.66% (below 0%: shrinking)	(34.29%)	0.00%
JONE Jones Energy, Inc.	$281.6M	— (loss-making)	—	−1.15% (below 0%: shrinking)	n/m	+48.67% (above 0%: growing)	92.10%	(2,506.03%)	Compare
Median of peers	—	—	—	—	—	—	—	—

All 39 Other stocks →

Sinovac Biotech, Ltd. (SVA) key facts

Strength: Sinovac Biotech, Ltd.’s revenue for fiscal 2025 (year ended December 2025) was $386.0 million, up 6.82% from fiscal 2024.
Sinovac Biotech, Ltd. (SVA) is an Other company in the Other sector, listed on Nasdaq.
As of October 14, 2026, SVA traded at $6.47, a market capitalization of $642.4 million.
Return on equity was −0.72% and debt-to-equity 0.06.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is 1.22 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.